U.S. markets closed

Bionomics Limited (BNOEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1690+0.0070 (+4.32%)
At close: 3:35PM EDT

Bionomics Limited

31 Dalgleish Street
Thebarton, SA 5031
61 8 8354 6100

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Errol B. De SouzaExec. Chairman280.58kN/A1953
Mr. Adrian HintonActing Chief Financial Officer205.06kN/AN/A
Prof. Paul RolanConsultant Chief Medical Officer of Clinical NeuroscienceN/AN/AN/A
Ms. Suzanne Irwin B.Com., FCISCompany Sec.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.

Corporate Governance

Bionomics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.